Skip to main content
SpringerLink
Log in

In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions

  • Article
  • Published:
Diabetologia Aims and scope Submit manuscript

Abstract

Aims/hypothesis

Secondary type 1 diabetes prevention trials require selection of participants with impending diabetes. HLA-A and -B alleles have been reported to promote disease progression. We investigated whether typing for HLA-B*18 and -B*39 may complement screening for HLA-DQ8, -DQ2 and -A*24 and autoantibodies (Abs) against islet antigen-2 (IA-2) and zinc transporter 8 (ZnT8) for predicting rapid progression to hyperglycaemia.

Methods

A registry-based group of 288 persistently autoantibody-positive (Ab+) offspring/siblings (aged 0–39 years) of known patients (Ab+ against insulin, GAD, IA-2 and/or ZnT8) were typed for HLA-DQ, -A and -B and monitored from the first Ab+ sample for development of diabetes within 5 years.

Results

Unlike HLA-B*39, HLA-B*18 was associated with accelerated disease progression, but only in HLA-DQ2 carriers (p < 0.006). In contrast, HLA-A*24 promoted progression preferentially in the presence of HLA-DQ8 (p < 0.002). In HLA-DQ2- and/or HLA-DQ8-positive relatives (n = 246), HLA-B*18 predicted impending diabetes (p = 0.015) in addition to HLA-A*24, HLA-DQ2/DQ8 and positivity for IA-2A or ZnT8A (p ≤ 0.004). HLA-B*18 interacted significantly with HLA-DQ2/DQ8 and HLA-A*24 in the presence of IA-2 and/or ZnT8 autoantibodies (p ≤ 0.009). Additional testing for HLA-B*18 and -A*24 significantly improved screening sensitivity for rapid progressors, from 38% to 53%, among relatives at high Ab-inferred risk carrying at least one genetic risk factor. Screening for HLA-B*18 increased sensitivity for progressors, from 17% to 28%, among individuals carrying ≥3 risk markers conferring >85% 5 year risk.

Conclusions/interpretation

These results reinforce the importance of HLA class I alleles in disease progression and quantify their added value for preparing prevention trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

Ab:

Autoantibody

Ab+ :

Autoantibody-positive

BDR:

Belgian Diabetes Registry

FDRs:

First-degree relatives

GADA:

GAD autoantibodies

IAA:

Insulin autoantibodies

IA-2:

Islet antigen-2

IA-2A:

IA-2 autoantibodies

IQR:

Interquartile range

ZnT8:

Zinc transporter 8

ZnT8A:

ZnT8 autoantibodies

References

  1. Mbunwe E, van der Auwera BJ, Vermeulen I et al (2013) HLA-A*24 is an independent predictor of 5-year progression to diabetes in autoantibody-positive first-degree relatives of type 1 diabetic patients. Diabetes 62:1345–1350

    Article  PubMed  CAS  Google Scholar 

  2. von Herrath M, Peakman M, Roep B (2013) Progress in immune-based therapies for type 1 diabetes. Clin Exp Immunol 172:186–202

    Article  Google Scholar 

  3. Tait BD, Colman PG, Morahan G et al (2003) HLA genes associated with autoimmunity and progression to disease in type 1 diabetes. Tissue Antigens 61:146–153

    Article  PubMed  CAS  Google Scholar 

  4. Lipponen K, Gombos Z, Kiviniemi M et al (2010) Effect of HLA class I and class II alleles on progression from autoantibody positivity to overt type 1 diabetes in children with risk-associated class II genotypes. Diabetes 59:3253–3256

    Article  PubMed  CAS  Google Scholar 

  5. Nejentsev S, Howson JM, Walker NM et al (2007) Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 450:887–892

    Article  PubMed  CAS  Google Scholar 

  6. Fennessy M, Metcalfe K, Hitman GA et al (1994) A gene in the HLA class I region contributes to susceptibility to IDDM in the Finnish population. Diabetologia 37:937–944

    Article  PubMed  CAS  Google Scholar 

  7. Valdes AM, Wapelhorst B, Concannon P, Erlich HA, Thomson G, Noble JA (2005) Extended DR3-D6S273-HLA-B haplotypes are associated with increased susceptibility to type 1 diabetes in US Caucasians. Tissue Antigens 65:115–119

    Article  PubMed  CAS  Google Scholar 

  8. Vermeulen I, Weets I, Costa O et al (2012) An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age. Diabetologia 55:413–420

    Article  PubMed  CAS  Google Scholar 

  9. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197

    Google Scholar 

  10. Middleton D (2000) PCR-SSOP class I and class II (DRBI). In: Hahn AB, Land GA, Strothman RM (eds), ASHI laboratory manual, 4th edition. American Society for Histocompatibility and Immunogenetics, Lenexa, p. V.C.2.1–23

  11. Greenbaum CJ, Buckingham B, Chase HP, Krischer J (2011) Metabolic tests to determine risk for type 1 diabetes in clinical trials. Diabetes Metab Res Rev 27:584–589

    Article  PubMed  CAS  Google Scholar 

  12. Xu P, Beam CA, Cuthbertson D, Sosenko JM, Skyler JS, Krischer JP (2012) Prognostic accuracy of immunologic and metabolic markers for type 1 diabetes in a high-risk population: receiver operating characteristic analysis. Diabetes Care 35:1975–1980

    Article  PubMed  CAS  Google Scholar 

  13. Honeyman MC, Harrison LC, Drummond B, Colman PG, Tait BD (1995) Analysis of families at risk for insulin-dependent diabetes mellitus reveals that HLA antigens influence progression to clinical disease. Mol Med 1:576–582

    PubMed  CAS  Google Scholar 

  14. Valdes AM, Erlich HA, Noble JA (2005) Human leukocyte antigen class I B and C loci contribute to type 1 diabetes (T1D) susceptibility and age at T1D onset. Hum Immunol 66:301–313

    Article  PubMed  CAS  Google Scholar 

  15. Kronenberg D, Knight RR, Estorninho M et al (2012) Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill beta-cells. Diabetes 61:1752–1759

    Article  PubMed  CAS  Google Scholar 

  16. Marron MP, Graser RT, Chapman HD, Serreze DV (2002) Functional evidence for the mediation of diabetogenic T cell responses by HLA-A2.1 MHC class I molecules through transgenic expression in NOD mice. Proc Natl Acad Sci U S A 99:13753–13758

    Article  PubMed  CAS  Google Scholar 

  17. van Belle TL, Coppieters KT, von Herrath MG (2011) Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 91:79–118

    Article  PubMed  Google Scholar 

  18. Vandemeulebroucke E, Keymeulen B, Decochez K et al (2010) Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients. Diabetologia 53:36–44

    Article  PubMed  CAS  Google Scholar 

  19. Long AE, Gillespie KM, Aitken RJ, Goode JC, Bingley PJ, Williams AJ (2013) Humoral responses to islet antigen-2 and zinc transporter 8 are attenuated in patients carrying HLA-A*24 alleles at the onset of type 1 diabetes. Diabetes. doi:10.2337/db12-1468

    PubMed  Google Scholar 

  20. Nakanishi K, Kobayashi T, Murase T, Naruse T, Nose Y, Inoko H (1999) Human leukocyte antigen-A24 and -DQA1*0301 in Japanese insulin-dependent diabetes mellitus: independent contributions to susceptibility to the disease and additive contributions to acceleration of beta-cell destruction. J Clin Endocrinol Metab 84:3721–3725

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors gratefully acknowledge the expert technical assistance of co-workers at the central unit of the Belgian Diabetes Registry (P. Goubert, C. Groven) and the reference laboratory of the Belgian Diabetes Registry (BDR) (V. Baeten, T. De Mesmaeker, H. Dewinter, N. Diependaele, S. Exterbille, T. Glorieux, T. Haulet, A. Ivens, D. Kesler, F. Lebleu, M. Van Molle, S. Vanderstraeten, K. Verhaeghen and A. Walgrave from the Department of Clinical Chemistry and Radio-immunology, University Hospital Brussels Free University-UZ Brussel, Brussels, Belgium; and G. De Block, E. Quartier, G. Schoonjans from the Brussels Free University-VUB, Brussels). The authors also thank the various university teams of co-workers for their excellent assistance in collecting samples and organising the fieldwork: L. Van Gaal, C. De Block, R. Braspenning, J. Michiels, J. Van Elven and J. Vertommen from the University Hospital Antwerp, Antwerp, Belgium; B. Keymeulen, K. Decochez, E. Vandemeulebroucke, U. Van de Velde from the University Hospital Brussels Free University-UZ Brussel, Brussels, Belgium; J. M. Kaufman, J. Ruige, A. Hutse, A. Rawoens and N. Steyaert from the University Hospital Ghent, Ghent, Belgium; and C. Mathieu, P. Gillard, M. Carpentier, M. Robijn, K. Rouffe, A. Schoonis and H. Morobé from the University Hospital Leuven, Leuven, Belgium. The authors sincerely thank all members of the BDR who contributed to the recruitment of relatives for the present study (list of names: see ESM Appendix).

Funding

The present work was supported by grants from the JDRF, Center Grant 4-2005-1327, the European Union (FP-7 project no. 241833), the Belgian Fund for Scientific Research (FWO Vlaanderen projects G.0319.01, G.0514.04, G.0311.07, G.0374.08 and G.0868.11; senior clinical research fellowships to I. Weets, K. Decochez and B. Keymeulen), the Research Council of the Brussels Free University (research fellowship to E. Mbunwe) and the Willy Gepts Fund (projects 3–2005 and 3/22-2007; University Hospital Brussels-UZ Brussel). J. C. Hutton received funding from DERC (NIH P30 DK57516), NIH R01 DK052068 and JDRF 4-2007-1056. The BDR was sponsored by the Belgian National Lottery, the ministries of Public Health of the Flemish and French Communities of Belgium, Hippo & Friends, WeightWatchers, Ortho-Clinical Diagnostics, Novo Nordisk Pharma, Lifescan, Roche Diagnostics, Bayer and Eli Lilly.

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript.

Contribution statement

All authors contributed to the design of the study, acquisition of data, statistical analysis, discussion and/or revision of the manuscript. All authors approved the final version.

Author information

Authors and Affiliations

  1. Diabetes Research Center, Brussels Free University-VUB, Laarbeeklaan 103, 1090, Brussels, Belgium

    E. Mbunwe, B. J. Van der Auwera, I. Weets, K. Decochez, E. Vandemeulebroucke, B. Keymeulen, C. van Schravendijk, D. G. Pipeleers & F. K. Gorus

  2. Department of Clinical Chemistry and Radio-immunology, University Hospital Brussels Free University-UZ Brussel, Brussels, Belgium

    I. Weets & F. K. Gorus

  3. Department of Endocrinology, OLV-Ziekenhuis, Aalst, Belgium

    P. Van Crombrugge

  4. Department of Endocrinology, ULB-Erasme Hospital, Brussels, Belgium

    L. Crenier

  5. Department of Diabetology, Paola Kinderziekenhuis, Antwerp, Belgium

    M. Coeckelberghs

  6. Department of Pediatrics, CHC Clinique Saint-Joseph, Liège, Belgium

    N. Seret

  7. Department of Diabetology, University Hospital Brussels Free University-UZ Brussel, Brussels, Belgium

    K. Decochez, E. Vandemeulebroucke & B. Keymeulen

  8. Department of Clinical and Experimental Medicine, University of Leuven-KUL and University Hospitals, Leuven, Belgium

    P. Gillard

  9. Barbara Davis Center for Childhood Diabetes, University of Colorado at Denver, Aurora, CO, USA

    J. M. Wenzlau & J. C. Hutton

Authors
  1. E. Mbunwe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. J. Van der Auwera
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Weets
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Van Crombrugge
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Crenier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Coeckelberghs
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N. Seret
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K. Decochez
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E. Vandemeulebroucke
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P. Gillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B. Keymeulen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C. van Schravendijk
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J. M. Wenzlau
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J. C. Hutton
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. D. G. Pipeleers
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. F. K. Gorus
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The Belgian Diabetes Registry

Corresponding author

Correspondence to I. Weets.

Additional information

A list of members of the Belgian Diabetes Registry is given in the ESM Appendix

We dedicate this paper to the memory of J. C. Hutton who passed away on December 18, 2012. He contributed to the design of the study, the discussion of the results and the first version of the manuscript

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM Appendix

(PDF 21 kb)

ESM Fig. 1

(PDF 41 kb)

ESM Table 1

(PDF 62 kb)

ESM Table 2

(PDF 47 kb)

ESM Table 3

(PDF 51 kb)

ESM Table 4

(PDF 69 kb)

ESM Table 5

(PDF 62 kb)

ESM Table 6

(PDF 60 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mbunwe, E., Van der Auwera, B.J., Weets, I. et al. In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions. Diabetologia 56, 1964–1970 (2013). https://doi.org/10.1007/s00125-013-2951-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00125-013-2951-8

Keywords

Search

Navigation